Livedo reticularis following drug interaction of sertraline and amantadine in a patient with obsessive-compulsive disorder and depression: A brief report
Advances in Pharmacology and Therapeutics Journal · 2022
DOI: 10.18502/aptj.v1i2.8672 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Pharmacology and Therapeutics Journal, 2022. Verfasst von Fatemeh Mohamadian Rasnani und 4 weiteren Autor:innen.
Themen: Depression
Abstract (Originalsprache)
Livedo reticularis (LR) is a cutaneous vascular pattern that presents with reticular patch morphology. LR is a manifestation of a wide range of diseases, from idiopathic to systemic. We reported the clinical image of a patient with obsessive-compulsive disorder (OCD) and LR associated with amantadine use. On examination, mild postural tremor was left-handed and had a kinetic tremor. Rest tremor and re-emerge tremor were detected in addition to mild rigidity and bradykinesia in the patient; we proposed probable drug-induced Parkinsonism. We should notice skin lesions after amantadine use and consider LR after the prescription of it. Also, co-administration of SSRIs and amantadine may increasethe probability of LR.
Zitieren
APA
Rasnani, F. M., Panahi, S., Zare, F., Bidaki, R., & Asadi, M. (2022). Livedo reticularis following drug interaction of sertraline and amantadine in a patient with obsessive-compulsive disorder and depression: A brief report. Advances in Pharmacology and Therapeutics Journal. https://doi.org/10.18502/aptj.v1i2.8672
Vancouver
Rasnani FM, Panahi S, Zare F, Bidaki R, Asadi M. Livedo reticularis following drug interaction of sertraline and amantadine in a patient with obsessive-compulsive disorder and depression: A brief report. Advances in Pharmacology and Therapeutics Journal. 2022. doi:10.18502/aptj.v1i2.8672
BibTeX
@article{Rasnani2022,
author = {Rasnani, Fatemeh Mohamadian and Panahi, Somayeh and Zare, Fatemeh and Bidaki, Reza and Asadi, Mohadeseh},
title = {Livedo reticularis following drug interaction of sertraline and amantadine in a patient with obsessive-compulsive disorder and depression: A brief report},
journal = {Advances in Pharmacology and Therapeutics Journal},
year = {2022},
doi = {10.18502/aptj.v1i2.8672}
}
EUVIMED